A phase II study on the treatment of advanced non-small cell lung cancer with brain metastasis by SRS sequential sintilimab

Inclusion Criteria:

• non-small cell lung cancer patients with less than brain metastases
• Patients must have received at least the first-line anti-tumor treatment, and the front-line treatment must include chemotherapy or targeted treatment with a platinum containing combination scheme, but not anti-PD-1 / L1 treatment
• Patients who have not received intracranial local treatment before

Exclusion Criteria:

• Patients who toke major surgery within 4 weeks prior to enrollment or had ununited wounds
• Patients with hemorrhage in intracranial metastasis